On Apr. 15, 2020, Bellicum Pharma announced closing of the sale of its Houston facility to The University of Texas MD Anderson Cancer Center at a purchase price of $15 million. In January 2020, Bellicum entered into an asset purchase agreement under which MD Anderson would acquire Bellicum’s approximately 60,000-square-foot Houston facility, including manufacturing, office and laboratory space.

Bellicum also entered into a master services agreement with MD Anderson. Following completion of the transaction, MD Anderson will operate the Houston facility for its own internal programs as well as to manufacture Bellicum’s GoCAR and other cellular therapy programs for clinical trials and potentially early commercial supply.